The Group's principal activities are developing, manufacturing and commercialization of immunobiotics. It operates through two segments: Biodefense: Focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. BioThrax(R), its marketed product is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. The Commercial segment focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. The Commercial product portfolio includes a typhoid vaccine candidate and a hepatitis B therapeutic vaccine candidate, both of which are in Phase II clinical development, a group B streptococcus vaccine candidate in Phase I clinical development and two vaccine candidates in preclinical development.
Alacra Alerts:
Receive alerts on the latest reports on Emergent BioSolutions Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
